TY - JOUR
T1 - Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis
AU - Bekele, Delamo I.
AU - Cheng, Elizabeth
AU - Reimold, Andreas
AU - Geier, Christian
AU - Ganuthula, Kavya
AU - Walsh, Jessica A.
AU - Clegg, Daniel O.
AU - Dubreuil, Maureen
AU - Kaushik, Prashant
AU - Ng, Bernard
AU - Chang, Elizabeth
AU - Duong, Ryan
AU - Park, Jina
AU - Kerr, Gail S.
N1 - Funding Information:
The other authors have disclosed no conflicts of interest. Dr. Kerr has received current and prior grant funding from Novartis, BMS and Pfizer. She currently serves on the advisory board for Janssen. Dr. Walsh has received consulting fees from AbbVie, Lilly, Novartis and UCB (all less than $10,000). She has also received research funding from AbbVie and Pfizer. Dr. Clegg has received VA Merit Review funding. Dr. Reimold has served as a consultant for Lilly (less than $10,000).
Publisher Copyright:
© 2021, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
PY - 2021
Y1 - 2021
N2 - Although tumor necrosis factor inhibitors (TNFi) have favorably altered the treatment landscape for patients with axial spondyloarthritis (axSpA), there is limited data regarding TNFi persistence and reasons for discontinuation. This is an observational time-to-event study utilizing data collected for a prospective multiple-disease registry of US Veterans with axSpA treated with TNFi therapies and recruited over a 10 year period. Clinical, serological, and comorbid parameters were collected. Corporate Data Warehouse Pharmacy files provided courses of the 5 TNFi agents, and response to treatment was documented. Individual TNFi persistence was established utilizing univariate and multivariate Cox proportional models, and reasons for discontinuation were obtained by physician chart review. Two-hundred and fifty-five axSpA patients received 731 TNFi courses. A majority of patients (84.3%) had TNFi persistence at 12 months; 63.5% and 47.1% at 24 and 36 months, respectively. Compared to adalimumab, infliximab demonstrated greater persistence, certolizumab the least. Age, smoking status, BMI, comorbidity burden, inflammatory markers and HLA-B27 did not predict TNFi persistence or discontinuation. Stroke and peripheral arterial disease increased the probability of TNFi discontinuation. Secondary non-response (SNR) was the most common reason for discontinuation (46% of all courses); non-adherence (6%) and clinical remission (2%) were uncommon. Pain score at enrollment, myocardial infarction, African American race and inflammatory bowel disease (IBD) predicted TNFi response. While initial persistence of TNFi treatment was high, a large proportion of the patients discontinued initial TNFi therapy by 3 years, primarily due to loss of efficacy. While further research identifying potential predictors of TNFi discontinuation in axSpA is warranted, access to alternate disease-modifying therapies is needed.
AB - Although tumor necrosis factor inhibitors (TNFi) have favorably altered the treatment landscape for patients with axial spondyloarthritis (axSpA), there is limited data regarding TNFi persistence and reasons for discontinuation. This is an observational time-to-event study utilizing data collected for a prospective multiple-disease registry of US Veterans with axSpA treated with TNFi therapies and recruited over a 10 year period. Clinical, serological, and comorbid parameters were collected. Corporate Data Warehouse Pharmacy files provided courses of the 5 TNFi agents, and response to treatment was documented. Individual TNFi persistence was established utilizing univariate and multivariate Cox proportional models, and reasons for discontinuation were obtained by physician chart review. Two-hundred and fifty-five axSpA patients received 731 TNFi courses. A majority of patients (84.3%) had TNFi persistence at 12 months; 63.5% and 47.1% at 24 and 36 months, respectively. Compared to adalimumab, infliximab demonstrated greater persistence, certolizumab the least. Age, smoking status, BMI, comorbidity burden, inflammatory markers and HLA-B27 did not predict TNFi persistence or discontinuation. Stroke and peripheral arterial disease increased the probability of TNFi discontinuation. Secondary non-response (SNR) was the most common reason for discontinuation (46% of all courses); non-adherence (6%) and clinical remission (2%) were uncommon. Pain score at enrollment, myocardial infarction, African American race and inflammatory bowel disease (IBD) predicted TNFi response. While initial persistence of TNFi treatment was high, a large proportion of the patients discontinued initial TNFi therapy by 3 years, primarily due to loss of efficacy. While further research identifying potential predictors of TNFi discontinuation in axSpA is warranted, access to alternate disease-modifying therapies is needed.
KW - Axial spondyloarthritis
KW - Medication persistence
KW - Real-world
KW - TNF inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85118388032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118388032&partnerID=8YFLogxK
U2 - 10.1007/s00296-021-05024-w
DO - 10.1007/s00296-021-05024-w
M3 - Article
C2 - 34724089
AN - SCOPUS:85118388032
SN - 0172-8172
JO - Rheumatology International
JF - Rheumatology International
ER -